Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Bicalutamide (Primary) ; Buserelin (Primary) ; Darolutamide (Primary) ; Degarelix (Primary) ; Flutamide (Primary) ; Goserelin (Primary) ; Histrelin (Primary) ; Leuprorelin (Primary) ; Relugolix (Primary) ; Triptorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms GUIDANCE
- 07 Jan 2022 Status changed from not yet recruiting to recruiting.
- 23 Sep 2021 New trial record